Featured essay
Fill finish drug product CDMO outsourcing capacityModern Catalyst Sterile fill-finish capacity has become the manufacturing bottleneck that defines CDMO strategy in 2025–2026. Sterile fill/finish capacity remains tight, and regulatory expectations are intensifying even as sponsors accelerate programs with fewer internal…
Read full essay